Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Position Raised by Barclays PLC

Barclays PLC raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 51.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 263,970 shares of the company's stock after purchasing an additional 89,909 shares during the period. Barclays PLC owned 0.50% of Janux Therapeutics worth $14,133,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. grew its stake in Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after purchasing an additional 442 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $139,000. Meeder Asset Management Inc. bought a new stake in shares of Janux Therapeutics in the 4th quarter valued at approximately $159,000. Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics during the 4th quarter valued at approximately $230,000. Finally, Cerity Partners LLC bought a new position in Janux Therapeutics during the fourth quarter worth $239,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the stock in a transaction dated Friday, March 7th. The stock was acquired at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the purchase, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have weighed in on JANX shares. Scotiabank lowered their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Wedbush restated an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Price Performance

Shares of JANX traded up $1.61 during trading hours on Wednesday, reaching $31.62. 830,568 shares of the company's stock traded hands, compared to its average volume of 851,217. Janux Therapeutics, Inc. has a twelve month low of $22.52 and a twelve month high of $71.71. The business's fifty day simple moving average is $30.38 and its two-hundred day simple moving average is $43.39. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -27.03 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.